Ribon Therapeutics rids preclinical work, trims staff to focus on two clinical PARP inhibitors
Ribon Therapeutics, a biotech looking to make next-generation oral PARP inhibitors, has ended preclinical and platform work to focus on two clinical programs.
“Cuts across …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.